Vor Biopharma Inc. (VOR)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash, providing runway through early 2029 and enabling Phase 3 clinical trial readouts in gMG and Sjögren's disease before requiring additional capital. Telitacicept's differentiation lies in upstream B-cell pathway inhibition, with promising efficacy signals across gMG, SjD, and IgAN, but faces intense competition and regulatory translation risk.
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vor Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ML Marc Larkins Johnson & Johnson | 53,732 | $2.62M | $986,519.52 | -$1.63M | -62.32% |
 David Kim Paradigm Biocapital Advisors LP | 1.75M | $22.89M | $31.97M | $9.08M | 39.68% |
| SRB Steve R. Bailey Frazier Life Sciences Management LP | 2.54M | $33.27M | $46.77M | $13.5M | 40.56% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 37 | $660.08 | $677.7 | $17.62 | 2.67% |
 Li Peng China Universal Asset Management Co. Ltd. | 7,368 | $118,374.16 | $134,760.72 | $16,386.56 | 13.84% |
Vor Biopharma Inc. (VOR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vor Biopharma Inc. ever had a stock split?
Vor Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jean-Paul Kress CEO | NASDAQ (NGS) Exchange | 929033207 CUSIP |
| US Country | 76 Employees | - Last Dividend | 19 Sep 2025 Last Split | 5 Feb 2021 IPO Date |
Overview
Vor Biopharma, Inc. is a clinical-stage biotechnology firm focused on the innovation of engineered hematopoietic stem cell (eHSC) therapies aimed at transforming the treatment landscape for cancer patients. With a strong emphasis on research and development, the company is pioneering the advancement of novel eHSC products to effectively combat acute myeloid leukemia (AML) and other hematological malignancies. Incorporated in 2015, Vor Biopharma is headquartered in Cambridge, Massachusetts, situating itself in one of the world’s leading biotech hubs to leverage cutting-edge science and technology in its quest to develop groundbreaking cancer treatments. Through its rigorous clinical programs and strategic collaborations, Vor Biopharma seeks to address the unmet medical needs of the cancer patient community.
Products and Services
- VOR33
Vor Biopharma's flagship product candidate, VOR33, represents a pioneering approach in the treatment of acute myeloid leukemia (AML) and other hematological malignancies. This engineered hematopoietic stem cell (eHSC) therapy is currently undergoing a phase 1/2 clinical trial designed to evaluate its safety and efficacy. Unique to VOR33, is its genetic modification to lack CD33, a protein ubiquitously expressed on the surface of AML cancer cells. By eliminating CD33 from hematopoietic stem cells, VOR33 aims to shield these cells from attacks by targeted therapies, such as CAR-T cells, bispecific antibodies, and antibody-drug conjugates, which are designed to target CD33-positive AML cells. This innovative approach has the potential to significantly enhance the effectiveness of existing cancer treatments while minimizing damage to healthy cells.
- Collaboration with Akron BioProducts
Vor Biopharma has established a strategic collaboration with Akron BioProducts to bolster its capabilities in developing and manufacturing critical components required for its eHSC therapies. This partnership focuses on the production of cGMP (current Good Manufacturing Practice) compliant nucleases, which are essential for the precise genetic modification of hematopoietic stem cells. This collaboration underscores Vor Biopharma’s commitment to adhering to the highest standards of manufacturing and quality assurance, ensuring that the therapies it develops are both safe and effective for patient use.
